RNA Splicing as a Therapeutic Target in Cancer

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• RNA splicing is a critical nuclear process for generating mature messenger RNA (mRNA).
• Dysregulation of RNA splicing is a common hallmark of cancer, driven by genetic, epigenetic, and machinery alterations.
• Altered splicing contributes to cancer development and progression.

Purpose of the Study:

• To review current therapeutic strategies that pharmacologically modulate RNA splicing in cancer.
• To discuss small molecules and oligonucleotides targeting the splicing machinery or mRNA transcripts.
• To present early clinical findings on splicing-modulating agents in cancer patients.

Main Methods:

• Review of existing literature on RNA splicing modulation in cancer.
• Analysis of therapeutic modalities including small molecules and oligonucleotides.
• Examination of early clinical trial data for splicing-targeted therapies.

Main Results:

• Multiple approaches exist to pharmacologically target RNA splicing.
• Small molecules and oligonucleotides show potential in modulating splicing processes.
• Early clinical trials indicate the feasibility and potential efficacy of these novel therapies.

Conclusions:

• RNA splicing represents a significant and actionable therapeutic target in oncology.
• Targeting RNA splicing offers a promising avenue for novel cancer treatments.
• Further research and clinical evaluation are warranted to fully realize the potential of splicing-based cancer therapies.